On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
REGULATORY
MHLW Panel Proposes Assessing Generic Makers’ Efforts toward Stable Supplies, Reflecting Results in Pricing
A study group under the Ministry of Health, Labor and Welfare (MHLW) compiled an interim report on the future of the generic industry on October 11, in which it floated a scheme whereby manufacturers are asked to disclose information on…
To read the full story
Related Article
- MHLW to Disclose Company Names under Generic Index Rule Possibly in FY2026
December 19, 2024
- Discussions on Generic Company Indices Make Headway towards Full Rollout in Next Revision
December 13, 2024
- Chuikyo Supports Full Rollout of Company Indices for Generics Manufacturers
November 7, 2024
- 120 APIs/Specs to Get Higher-than-Peer Prices with Generic Company Indicators: MHLW Simulation
December 14, 2023
- Japan to Adopt Generic Company Indices for Drug Pricing on Pilot Basis from FY2024
November 20, 2023
- Generic Study Group Discusses Industry Shake-Up through Consortia
November 14, 2023
- No Objections to Reflecting Company Indices for Generic Supplies in Pricing: Chuikyo
October 30, 2023
- JGA Vows Cooperation after Generic Panel’s Interim Report
October 20, 2023
REGULATORY
- Chuikyo OKs Tougher CEA Price Cuts for Drugs Tagged “Cost Increase”
November 12, 2026
- Chuikyo Weighs “Agile Response” to MFN as Providers Question Drug Lag, Loss Impact
November 12, 2026
- Japan to List Eylea Biosimilars from SamChunDang, Celltrion on Nov. 13
November 12, 2026
- PMDA Sees Little Need for Separate Dosage Form Category for Mini-Tablets
November 11, 2026
- Japan Eyes Nationwide Probe into Wartime Drug Trials on Leprosy Patients
November 11, 2026
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…